Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Raw Materials (2016 - 2026)

Amphastar Pharmaceuticals has reported Raw Materials over the past 11 years, most recently at $106.8 million for Q4 2025.

  • For Q4 2025, Raw Materials rose 31.06% year-over-year to $106.8 million; the TTM value through Dec 2025 reached $106.8 million, up 31.06%, while the annual FY2025 figure was $106.8 million, 31.06% up from the prior year.
  • Raw Materials for Q4 2025 was $106.8 million at Amphastar Pharmaceuticals, up from $105.8 million in the prior quarter.
  • Over five years, Raw Materials peaked at $106.8 million in Q4 2025 and troughed at $40.4 million in Q1 2022.
  • A 5-year average of $61.2 million and a median of $49.0 million in 2023 define the central range for Raw Materials.
  • Biggest five-year swings in Raw Materials: decreased 20.63% in 2021 and later surged 100.84% in 2025.
  • Year by year, Raw Materials stood at $41.9 million in 2021, then grew by 13.75% to $47.6 million in 2022, then rose by 5.2% to $50.1 million in 2023, then soared by 62.76% to $81.5 million in 2024, then skyrocketed by 31.06% to $106.8 million in 2025.
  • Business Quant data shows Raw Materials for AMPH at $106.8 million in Q4 2025, $105.8 million in Q3 2025, and $106.5 million in Q2 2025.